Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS.

Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.

2.

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS.

Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.

3.

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW.

J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17.

4.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team.

Am J Obstet Gynecol. 2005 Nov;193(5):1630-9. Erratum in: Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

PMID:
16260202
5.

Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.

Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.

Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.

6.
7.

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.

J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.

8.

Screening for ovarian cancer in the general population.

Gentry-Maharaj A, Menon U.

Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):243-56. doi: 10.1016/j.bpobgyn.2011.11.006. Epub 2011 Dec 17. Review.

PMID:
22182415
10.

Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management.

Spiliotis J, Halkia E, Roukos DH.

Expert Rev Mol Diagn. 2011 Jun;11(5):465-7. doi: 10.1586/ERM.11.29. No abstract available.

PMID:
21707454
11.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

12.

Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.

Bodelon C, Pfeiffer RM, Buys SS, Black A, Sherman ME.

J Natl Cancer Inst. 2014 Sep 13;106(10). pii: dju262. doi: 10.1093/jnci/dju262. Print 2014 Oct.

13.
14.

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.

Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR.

Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.

PMID:
19100916
15.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.

J Clin Oncol. 2007 Apr 10;25(11):1383-9.

PMID:
17416858
17.

Physician knowledge and awareness of CA-125 as a screen for ovarian cancer in the asymptomatic, average-risk population.

Stewart SL, Rim SH, Gelb CA.

Health Educ Behav. 2012 Feb;39(1):57-66. doi: 10.1177/1090198111407185. Epub 2011 Jun 16.

PMID:
21680807
18.

Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.

Whitmore SE, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Helzlsouer KJ, Rosenshein NB.

Gynecol Oncol. 1997 May;65(2):241-4.

PMID:
9159332
19.

Screening for ovarian cancer: a pilot randomised controlled trial.

Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH.

Lancet. 1999 Apr 10;353(9160):1207-10.

PMID:
10217079
20.

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T.

Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20. Epub 2007 Jul 21.

PMID:
17645503

Supplemental Content

Support Center